Response to MEK inhibition with trametinib and tyrosine kinase inhibition with imatinib in multifocal histiocytic sarcoma

समान संसाधन

• Comment on “MEK inhibition with trametinib and tyrosine kinase inhibition with imatinib in multifocal histiocytic sarcoma”
  द्वारा: Voruz, Sophie, और अन्य
  प्रकाशित: (2018)
• Trametinib in Histiocytic Sarcoma with an Activating MAP2K1 (MEK1) Mutation
  द्वारा: Gounder, Mrinal M., और अन्य
  प्रकाशित: (2018)
• Efficacy of MEK Inhibition in Patients with Histiocytic Neoplasms
  द्वारा: Diamond, Eli L., और अन्य
  प्रकाशित: (2019)
• Trametinib Induces the Stabilization of a Dual GNAQ p.Gly48Leu- and FGFR4 p.Cys172Gly-Mutated Uveal Melanoma. The Role of Molecular Modelling in Personalized Oncology
  द्वारा: Krebs, Fanny S., और अन्य
  प्रकाशित: (2020)
• MEK inhibition with trametinib is a successful therapy in ganglioglioma
  द्वारा: Daniel, Eliza Baird, और अन्य
  प्रकाशित: (2020)